Granted Patent B2

US 10,045,971 · App. 15/005,222 · Granted Aug 14, 2018

Inventors: Daniel Cohen (Saint Cloud, FR); Serguei Nabirochkin (Chatenay-Malabry, FR); Ilya Chumakov (Vaux-le-Penil, FR); Rodolphe Hajj (Saint Germain en Laye, FR)

Assignee: PHARNEXT

A61K31/44A61K31/137A61K31/138A61K31/145A61K31/164A61K31/185A61K31/195A61K31/197A61K31/42A61K31/428A61K31/445A61K31/64A61K45/06A61K9/2004

Abstract

Claims (30)

1. A method of treating amyotrophic lateral sclerosis (ALS) or a related motor neuron disorder selected from the group consisting of primary lateral sclerosis, progressive muscular atrophy, pseudobulbar palsy and progressive bulbar palsy in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a compound selected from sulfisoxazole or torasemide, or salts, or prodrugs, or sustained-release formulations thereof, in combination with at least one second different compound selected from sulfisoxazole, torasemide or riluzole, or salts, or prodrugs, or sustained-release formulations thereof.

2. The method of claim 1 , wherein the treatment of ALS or a related motor neuron disorder reduces motor neuron degeneration in said subject.

3. The method of claim 1 , comprising administering one of the following combinations of compounds:

torasemide and sulfisoxazole,

torasemide and riluzole,

sulfisoxazole and riluzole, or

torasemide, sulfisoxazole and riluzole,

or salts, or prodrugs, or sustained-release formulations of each of said compounds.

4. The method of claim 1 , wherein the compounds are administered with a pharmaceutically acceptable carrier or excipient.

5. The method of claim 1 , wherein the compounds are administered repeatedly to the subject.

6. The method of claim 1 , wherein the compounds are formulated or administered together, separately or sequentially.

7. The method of claim 6 , wherein the compounds are formulated together.

8. The method of claim 3 , wherein, when riluzole, or a salt, prodrug, or sustained-release formulation thereof, is present in the combination of compounds, it is administered alternately with the sulfisoxazole or torasemide, or the combination thereof, or the salts, or prodrugs, or sustained-release formulations thereof.

9. The method of claim 1 , wherein, when sulfisoxazole is present in the combination of compounds, it is administered in a dosage of less than 800 mg per day.

10. The method of claim 1 , wherein, when torasemide is present in the combination of compounds, it is administered in a dosage from about 0.05 to 4 mg per day.

11. The method of claim 1 , wherein, when riluzole is present in the combination of compounds, it is administered in a dosage from about 0.01 to 50 mg per day.

12. The method of claim 1 , wherein said compounds are administered orally.

13. A pharmaceutical composition comprising one of the following combinations of compounds:

torasemide and sulfisoxazole,

torasemide and riluzole,

sulfisoxazole and riluzole, or

torasemide, sulfisoxazole and riluzole,

or salts, or prodrugs, or sustained-release formulations of each of said compounds.

14. A method for protecting neuromuscular junctions against glutamate toxicity in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from sulfisoxazole or torasemide, or salts, or prodrugs, or sustained-release formulations thereof, in combination with at least one second different compound selected from sulfisoxazole, torasemide or riluzole, or salts, or prodrugs, or sustained-release formulations thereof.

15. A method in accordance with claim 14 , comprising administering one of the following combinations of compounds:

torasemide and sulfisoxazole,

torasemide and riluzole,

sulfisoxazole and riluzole, or

torasemide, sulfisoxazole and riluzole,

or salts, or prodrugs, or sustained-release formulations of each of said compounds.

Assignments (3)

Priority Claims (2)

Continuity (11)